No retraction, correction or concern found when last checked on Oct 22, 2026.
Antiviral activity of silver nanoparticle/chitosan composites against H1N1 influenza A virus
Yasutaka Mori, Takeshi Ono, Yasushi Miyahira and 3 more
Nanoscale Research Letters · 2013
Abstract
Silver nanoparticle (Ag NP)/chitosan (Ch) composites with antiviral activity against H1N1 influenza A virus were prepared. The Ag NP/Ch composites were obtained as yellow or brown floc-like powders following reaction at room temperature in aqueous medium. Ag NPs (3.5, 6.5, and 12.9 nm average diameters) were embedded into the chitosan matrix without aggregation or size alternation. The antiviral activity of the Ag NP/Ch composites was evaluated by comparing the TCID 50 ratio of viral suspensions treated with the composites to untreated suspensions. For all sizes of Ag NPs tested, antiviral activity against H1N1 influenza A virus increased as the concentration of Ag NPs increased; chitosan alone exhibited no antiviral activity. Size dependence of the Ag NPs on antiviral activity was also observed: antiviral activity was generally stronger with smaller Ag NPs in the composites. These results indicate that Ag NP/Ch composites interacting with viruses exhibit antiviral activity.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.
Background
Silver nanoparticles (Ag NPs) are well-known antimicrobial materials effective against many types of bacteria and fungi. The antibacterial and antifungal activities of Ag NPs are mainly due to the inhibition of respiratory enzymes by released Ag+ ions. Recently, the antimicrobial activities of Ag NPs against viruses such as HIV-1, hepatitis B, herpes simplex, respiratory syncytial, monkeypox, Tacaribe, and H1N1 influenza A virus have also been investigated. Unlike its antibacterial and antifungal activities, the major antiviral mechanism of Ag NPs is likely the physical inhibition of binding between the virus and host cell. A dependence of the size of Ag NPs on antiviral activity was observed for the viruses mentioned above; for example, Ag NPs smaller than 10 nm specifically inhibited infection by HIV-1. This property of Ag NPs holds promise that antimicrobial materials based on Ag NPs will be effective against many types of bacteria, fungi, and viruses.
On the other hand, there are some concerns about the biological and environmental risks of Ag NPs. It is known that Ag NPs have adverse effects, such as cytotoxicity and genotoxicity on aquatic organisms like fish, and can inhibit photosynthesis in algae. One study on mammals showed a significant decline in mouse spermatogonial stem cells following the administration of Ag NPs. Therefore, preventing the diffusion and intake of Ag NPs into the environment and the biosphere are important considerations in the design of antimicrobial materials containing Ag NPs. One approach would be the fixation of Ag NPs into matrices; for example, Fayaz et al. have prepared Ag NP-coated polyurethane and have demonstrated its antiviral activity against HIV-1 and herpes simplex virus. Nevertheless, the efficacy and mechanism of action of such Ag NP-fixed antiviral materials against various viral strains are not well investigated.
In this paper, the antiviral activity of Ag NP/polymer composites against H1N1 influenza A virus was investigated. Chitosan (Ch), which is the main constituent of the exoskeleton of crustaceans and exhibits strong antibacterial activity, was used as the matrix polymer. Controlling the size of Ag NPs is as important to antiviral activity as the composition of the Ag NPs. We previously demonstrated an environmentally friendly process for producing Ag NPs with a narrow size distribution. This process uses only three materials: a silver-containing glass powder as an Ag+ supplier, glucose as a reducing agent for Ag+, and water as a solvent. The stabilizing agent for Ag NPs is caramel, which is generated from glucose during heating to reduce Ag+. In this work, Ag NPs synthesized by this process were used to make the Ag NP/Ch composites, since the size of the Ag NPs could be easily controlled without the use or production of hazardous materials. Ag NP/Ch composites were synthesized in aqueous media at room temperature by mixing a chitosan solution and an Ag NP suspension. The surface and internal structure of the synthesized Ag NP/Ch composites were observed by scanning and transmission electron microscopies, respectively. The effect of introducing a small amount of Ag NPs into the chitosan matrices and the effect of the size of the Ag NPs were evaluated with respect to the antiviral activity of the composites.
Materials
Ag NP suspensions were synthesized from silver-containing glass powder (BSP21, silver content 1 wt%, average grain size 10 μm, Kankyo Science, Kyoto, Japan) and glucose aqueous solution, as described previously. Ag NPs used in this work were spherical; their characteristics are summarized in Table 1. Phosphate-buffered saline (PBS), methanol, Giemsa stain solution, and 5 M hydrochloric acid (HCl) and 5 M sodium hydroxide (NaOH) aqueous solutions were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan) and used without further purification. Chitosan solution (10 mg/mL) was prepared by mixing 0.1 g chitosan (average molecular weight 54 kg/mol, deacetylation ratio 84%; Yaizu Suisankagaku Industry Co., Ltd., Shizuoka, Japan), 10 mL of PBS, and 100 μL of 5 M HCl; following complete dissolution of the chitosan, the solution was filter-sterilized by passage through a 0.2-μm filter. Bovine serum albumin (BSA) solution was prepared using BSA powder (Sigma-Aldrich Japan, Tokyo, Japan) and PBS, then filter-sterilized as above. Trypsin was obtained from Life Technologies Co., (Carlsbad, CA, USA). Dulbecco's Modified Eagle Medium (DMEM, high glucose) was purchased from Sigma-Aldrich Japan (Tokyo, Japan).
Synthesis of Ag NP/Ch composites
Chitosan solution (100 μL, 10 mg/mL) was mixed with Ag NP solution (0.25 to 4.5 mL) and 40 μL 5 M NaOH at room temperature, followed by vigorous stirring to precipitate the Ag NP/Ch composite. The obtained Ag NP/Ch composite was centrifuged at 6,000 rpm for 10 min. The supernatant was analyzed using a UV-visible spectrometer (JASCO V-630, Tokyo, Japan) to estimate the amount of unreacted Ag NPs. Centrifuged composites were washed with 1 mL PBS, followed by centrifugation at 6,000 rpm for 10 min. The washing process was repeated twice. The washed Ag NP/Ch composite was suspended in 250 μL PBS and used in antiviral assays the same day. Synthesis of the Ag NP/Ch composites was carried out in a laminar flow cabinet to prevent biological contamination.
Microscopy observations
Scanning electron microscopy (SEM) specimens of the composites were prepared by casting 5 μL of a water dispersion of the Ag NP/Ch composite, followed by drying at room temperature. Osmium plasma coating was conducted to enhance the conductivity of the specimens. Dried samples were coated using a plasma multi-coater PMC-5000 (Meiwafosis Co., Ltd., Tokyo, Japan). SEM observation was performed using a JSM-6340F (JEOL, Tokyo, Japan) at 5 kV. Transmission electron microscopy (TEM) specimens of the Ag NPs and Ag NP composites were prepared by casting 5 μL of Ag NP solution or a water dispersion of the composite onto a carbon-coated copper microgrid. Excess solution was removed using filter paper, and the specimens were dried at room temperature. Further staining was not carried out for any specimen. TEM observation was performed using a JEM-1010 (JEOL) at 80 kV.
Assaying the antiviral activity of the Ag NP/Ch composites
Human influenza A virus (A/PR/8/34 (H1N1)), obtained from Life Technologies Co., was used and assayed using the fifty-percent tissue culture infectious dose (TCID50) method. Viral suspension in PBS (250 μL, titer ca. 1,000 TCID50/mL) was added to 250 μL Ag NP/Ch composite suspension. The mixture was stirred vigorously for 5 s and then left at room temperature for 1 h to allow the virus and composite particles to interact. Then, the mixture was centrifuged at 6,000 rpm for 10 min to remove the composite particles. The supernatant (50 μL) was subjected to two-fold serial dilution with PBS 11 times in a 96-well cell culture plate sown with Madin-Darby canine kidney (MDCK) cells. Eight duplicate dilution series were prepared and assayed for each Ag NP/Ch sample. Samples were incubated at 37°C and 5% CO2 for 1 h to allow viral infection of the MDCK cells. MDCK cells were maintained by adding 50 μL DMEM (with the addition of 0.4% of BSA and 5 ppm of trypsin) to each well immediately following infection and again 5 days post-infection. Seven days post-infection, the living cells were fixed with methanol and stained with 5% Giemsa stain solution. The TCID50 of the sample solution was calculated from the number of infected wells using the Reed-Muench method. The antiviral activity of the Ag NP/Ch composite was estimated as the TCID50 ratio of the Ag NP/Ch-treated supernatant to the control (untreated) viral suspension.
Results and discussion
Ag NP/Ch composites were synthesized by mixing a chitosan acidic aqueous solution with an Ag NP suspension. Chitosan is water soluble in acidic conditions due to protonation of primary amines in the chitosan chains. The Ag NP suspension was also acidic (pH 5.23 to 6.25). Although the acidity of these two solutions was maintained during mixing, partial precipitation of the Ag NP/Ch composites was observed at all conditions tested, suggesting that decreased solubility of the chitosan chains was induced by the binding of Ag NPs to the chitosan amino and hydroxyl groups. Addition of excess NaOH completely precipitated the composite. Figure 1 shows a typical SEM micrograph of the composite. Ag NP/Ch composites were obtained as flocculated, aggregated, spherical sub-micrometer particles. The composites were yellow or brown; darker composites were obtained when larger amounts of Ag NPs were reacted with the chitosan. Figure 2 shows UV-visible spectra of the original Ag NP suspension and of the reaction mixes containing high amounts of Ag NP. Since spherical Ag NPs provide a peak near 400 nm, the absence of this peak shows that Ag NPs are not present in the supernatant of the post-reaction mixture and that the Ag NPs were completely bound to the chitosan.
TEM micrographs of the Ag NPs and Ag NP/Ch composites are shown in Figure 3. Compared to Ag NPs before reaction, Ag NPs in the composites are dispersed in the chitosan matrix and appear as uneven gray domains. The thickness of the TEM specimen of the composites is uneven due to the direct casting of the composite floc. Uneven contrast of the chitosan domains is due to the uneven thickness of the specimen. Ag NPs in thick areas of the chitosan matrix are overlapped. Meanwhile, Ag NPs in thin areas appeared non-overlapped. The particle sizes of Ag NPs in the composites are similar to that of the original Ag NPs. Although some minor aggregation of Ag NPs was observed, there was no macroscopic aggregation, showing that the particle size of the Ag NPs in the Ag NP/Ch composites was controlled.
Figure 4 shows the dependence of particle size and amount of Ag NPs on the antiviral activity of the composites against influenza A virus. The TCID50 ratios of viral suspensions treated with Ag NPs and Ag NP/Ch composites to untreated suspensions were used to gauge the antiviral activity of the materials. For all Ag NPs tested, the antiviral activity of the Ag NP/Ch composites increased with increasing amount of Ag NPs. No antiviral activity was observed with chitosan alone, showing that the antiviral activity of the composites was due to the bound Ag NPs. The effect of size of the Ag NPs in the composites was also observed: for similar concentrations of Ag NPs, stronger antiviral activity was generally observed with composites containing smaller Ag NPs. This size effect was most prominent when less than 100 μg of Ag NPs was added to 1 mg of chitosan. No increase in antiviral activity was observed above 200 μg of Ag NPs per 1 mg of chitosan, irrespective of the size of the Ag NPs.
Previous studies showed that Ag NPs have antiviral activity against influenza A virus. Although the mechanism of action has not been well investigated, it is likely that the antiviral activity of Ag NPs against several other types of viruses is due to direct binding of the Ag NPs to viral envelope glycoproteins, thereby inhibiting viral penetration into the host cell. The effect of the size of Ag NPs on antiviral activity was usually observed, suggesting spatial restriction of binding between virions and Ag NPs. For the Ag NP/Ch composites, further spatial restriction due to the chitosan matrix would be expected to prevent or weaken the interaction between virions and Ag NPs. On the other hand, physical binding of virions to the composites could directly inhibit viral contact with host cells since the virus-treated composites were removed from the assay solution prior to infection of the host cells. When embedded Ag NPs could interact with the virions, the interaction between the virions and the composites should increase with increased concentration of Ag NPs in the composites; this is supported by the experimental results on the relationship between the antiviral activity and the concentration of Ag NPs. The effect of the size of Ag NPs in the composites on antiviral activity suggests that influenza A virus interacted selectively with smaller Ag NPs, as previously reported for other types of viruses. However, the size dependence of free Ag NPs on antiviral activity against influenza A virus has not been studied. To obtain more effective Ag NP-embedded antiviral materials, detailed studies of the mechanism of antiviral action of both free and embedded Ag NPs are required. The effects of the microscopic structure and the properties of Ag NP-embedded materials on antiviral activity should also be investigated in the future. Nonetheless, this study clearly demonstrates the feasibility of using Ag NPs to impart antiviral activity to chitosan and lower concerns about the risk of diffusion of Ag NPs in the environment.
Conclusions
Ag NP/Ch composites with antiviral activity against influenza A virus were synthesized in aqueous medium. The composites were obtained as yellow or brown flocs; unreacted Ag NPs were not detected in the residual solution. The particle size of the Ag NPs in the composites was similar to that of the Ag NPs used to synthesize the composites. The antiviral activity of the composites was determined from the decreased TCID50 ratio of viral suspensions after treatment with the composites. For all sizes of Ag NPs tested, the antiviral activity of the Ag NP/Ch composites increased as the amount of Ag NPs increased. Stronger antiviral activity was generally observed with composites containing smaller Ag NPs for comparable concentrations of Ag NPs. Neat chitosan did not exhibit antiviral activity, suggesting that Ag NPs are essential for the antiviral activity of the composites. Although the antiviral mechanism of the composites remains to be investigated, the experimental results showing the relationship between antiviral activity and the concentration of Ag NPs suggest that the virions and composites interacted. Consequently, detailed studies of the antiviral mechanism of the Ag NP/Ch composites could lead to the development of practical Ag NP-containing materials that will reduce concerns about the risks of diffusion of Ag NPs into the environment.
Abbreviations
Ag NP: Silver nanoparticle; Ch: Chitosan; SEM: Scanning electron microscopy; TEM: Transmission electron microscopy; TCID50: Fifty-percent tissue culture infectious dose.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YMo designed the research, performed the experiments, and drafted the manuscript and the figures. TO guided and performed the viral study. YMi supervised the virus study. VQN performed some of the experiments. TM participated in the design of the research. MI supervised and coordinated the study and approved the manuscript. All authors read and approved the final manuscript.
Authors' information
YMo is a technical official of the Japan Air Self-Defense Force. MI and YMi are professors of the National Defense Medical College. TO is a research associate of the National Defense Medical College. TM is a professor of the Tokyo Metropolitan University. VQN is a graduate student of the Tokyo Metropolitan University.
References 30
- 1.
Pal S Tak YK Song JM Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium Escherichia coliAppl Environ Microbiol2007 7317121720
Not in our library10.1128/aem.02218-06
- 2.
Sondi I Salopek-Sondi B Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteriaJ Colloid Interface Sci2004 275177182
Not in our library10.1016/j.jcis.2004.02.012
- 3.
Morones JR Elechiguerra JL Camacho A Holt K Kouri JB Ramirez JT Yacaman MJ The bactericidal effect of silver nanoparticlesNanotechnology2005 1623462353
Not in our library10.1088/0957-4484/16/10/059
- 4.
Gajbhiye M Kesharwani J Ingle A Gade A Rai M Fungus-mediated synthesis of silver nanoparticles and their activity against pathogenic fungi in combination with fluconazoleNanomedicine2009 5382386
Not in our library10.1016/j.nano.2009.06.005
- 5.
Liau SY Read DC Pugh WJ Furr JR Russell AD Interaction of silver nitrate with readily identifiable groups: relationship to the antibacterial action of silver ionsLett Appl Microbiol1997 25279283
Not in our library10.1046/j.1472-765x.1997.00219.x
- 6.
- 7.
Trefry JC Wooley DP Rapid assessment of antiviral activity and cytotoxicity of silver nanoparticles using a novel application of the tetrazolium-based colorimetric assayJ Virol Methods2012 1831924
Not in our library10.1016/j.jviromet.2012.03.014
- 8.
Lu L Sun RW Chen R Hui CK Ho CM Luk JM Lau GK Che CM Silver nanoparticles inhibit hepatitis B virus replicationAntivir Ther2008 13253262
Not in our library
- 9.
Baram-Pinto D Shukla S Perkas N Gedanken A Sarid R Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonateBioconjugate Chem2009 2014971502
Not in our library10.1021/bc900215b
- 10.
Sun L Singh AK Vig K Pillai SR Singh SR Silver nanoparticles inhibit replication of respiratory syncytial virusJ Biomed Nanotechnol2008 4149158
Not in our library
- 11.
Rogers JV Parkinson CV Choi YW Speshock JL Hussain SM A preliminary assessment of silver nanoparticle inhibition of monkeypox virus plaque formationNanoscale Res Lett2008 3129133
Not in our library10.1007/s11671-008-9128-2
- 12.
- 13.
Mehrbod P Motamed N Tabatabaian M Soleimani ER Amini E Shahidi M Kheiri MT In vitro antiviral effect of "nanosilver" on influenza virusDARU J Pharm Sci2009 178893
Not in our library
- 14.
Xiang DX Chen Q Pang L Zheng CL Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitroJ Virol Methods2011 178137142
Not in our library10.1016/j.jviromet.2011.09.003
- 15.
Wise JP Sr Goodale BC Wise SS Craig GA Pongan AF Walter RB Thompson WD Ng AK Aboueissa AM Mitani H Spalding MJ Mason MD Silver nanospheres are cytotoxic and genotoxic to fish cellsAquat Toxicol2010 973441
Not in our library10.1016/j.aquatox.2009.11.016
- 16.
Navarro E Piccapietra F Wagner B Marconi F Kaegi R Odzak N Sigg L Behra R Toxicity of silver nanoparticles to Chlamydomonas reinhardtiiEnviron Sci Technol2008 4289598964
Not in our library10.1021/es801785m
- 17.
Braydich-Stolle LK Lucas B Schrand A Murdock RC Lee T Schlager JJ Hussain SM Hofmann MC Silver nanoparticles disrupt GDNF/Fyn kinase signaling in spermatogonial stem cellsToxicol Sci2010 116577589
Not in our library10.1093/toxsci/kfq148
- 18.
Matyjas-Zgondek E Bacciarelli A Rybicki E Szynkowska MI Kołodziejczyk M Antibacterial properties of silver-finished textilesFibres Text East Eur2008 16101107
Not in our library
- 19.
Filipowska B Rybicki E Walawska A Matyjas-Zgondek E New method for the antibacterial and antifungal modification of silver finished textilesFibres Text East Eur2011 19124128
Not in our library
- 20.
Murugadoss A Chattopadhyay A A ‘green’ chitosan–silver nanoparticle composite as a heterogeneous as well as micro-heterogeneous catalystNanotechnology2008 19015603
Not in our library10.1088/0957-4484/19/01/015603
- 21.
Damm C Münstedt H Kinetic aspects of the silver ion release from antimicrobial polyamide/silver nanocompositesAppl Phys A2008 91479486
Not in our library10.1007/s00339-008-4434-1
- 22.
Sanpui P Murugadoss A Prasad PV Ghosh SS Chattopadhyay A The antibacterial properties of a novel chitosan-Ag-nanoparticle compositeInt J Food Microbiol2008 124142146
Not in our library10.1016/j.ijfoodmicro.2008.03.004
- 23.
Fayaz AM Ao Z Girilal M Chen L Xiao X Kalaichelvan PT Yao X Inactivation of microbial infectiousness by silver nanoparticles-coated condom: a new approach to inhibit HIV- and HSV-transmitted infectionInt J Nanomed2012 750075018
Not in our library10.2147/ijn.s34973
- 24.
Shi C Zhu Y Ran X Wang M Su Y Cheng T Therapeutic potential of chitosan and its derivatives in regenerative medicineJ Surg Res2006 133185192
Not in our library10.1016/j.jss.2005.12.013
- 25.
Mori Y Tagawa T Fujita M Kuno T Suzuki S Matsui T Ishihara M Simple and environmentally friendly preparation and size control of silver nanoparticles using an inhomogeneous system with silver-containing glass powderJ Nanopart Res2011 1327992806
Not in our library10.1007/s11051-010-0168-z
- 26.
Reed LJ Muench H A simple method of estimating fifty per cent endpointsAm J Hyg1938 27493497
Not in our library
- 27.
LaBarre DD Lowy RJ Improvements in methods for calculating virus titer estimates from TCID50 and plaque assaysJ Virol Methods2001 96107126
Not in our library10.1016/s0166-0934(01)00316-0
- 28.
An J Luo Q Yuan X Wang D Li X Preparation and characterization of silver-chitosan nanocomposite particles with antimicrobial activityJ Appl Polym Sci2011 12031803189
Not in our library10.1002/app.33532
- 29.
Sosa IO Noguez C Barrera RG Optical properties of metal nanoparticles with arbitrary shapesJ Phys Chem B2003 10762696275
Not in our library10.1021/jp0274076
- 30.
Cited by papers we hold 9
- Iron oxide nanoparticles and their pharmaceutical applications · 2022Not checked
- An Updated Review on Silver Nanoparticles in Biomedicine · 2020No notice
- Silver nanoparticles: Synthesis, medical applications and biosafety · 2020No notice
- Antiviral Potential of Nanoparticles—Can Nanoparticles Fight Against Coronaviruses? · 2020No notice
- Silver Nanoparticles: Mechanism of Action and Probable Bio-Application · 2020No notice
- The Potential of Silver Nanoparticles for Antiviral and Antibacterial Applications: A Mechanism of Action · 2020No notice
- Metal-Based Nanoparticles for the Treatment of Infectious Diseases · 2017No notice
- Antiviral Activity of Graphene–Silver Nanocomposites against Non-Enveloped and Enveloped Viruses · 2016No notice
- Nanoparticles: Alternatives Against Drug-Resistant Pathogenic Microbes · 2016No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.